Compounders Research Compare

Definium Therapeutics, Inc.(DFTX)

Biotechnology · New York, NY

$35.80-0.43 (-1.20%)

Delayed quote: Oct 6, 2026, 11:31 AM EDT

About Definium Therapeutics, Inc.

Definium Therapeutics, Inc. operates as a clinical-stage biopharmaceutical firm dedicated to developing innovative therapeutic solutions for various brain health and neurological disorders. Its pipeline features key experimental drug candidates like MM120, which is currently undergoing Phase 3 clinical trials for generalized anxiety disorder (GAD) and attention deficit hyperactivity disorder (ADHD). Another significant compound, MM402 – an R-enantiomer of 3,4-methylenedioxymethamphetamine – is in Phase 1 trials, targeting the fundamental symptoms of autism spectrum disorder. The company maintains its headquarters in New York, New York.

New York, NY

106 employees

Healthcare / Biotechnology

Sector: Healthcare
Industry: Biotechnology
CEO: Robert Barrow

View full financials

EV/EBIT Ratio: N/A

Basis: Current FMP quote-based enterprise value / four-quarter operating income. Source: stored company filings and market data; unavailable inputs remain N/A.

The EV/EBIT ratio is N/A as of 2026-10-06T15:32:37.926Z.

Stored calculation inputs

Calculation as of: 2026-10-06T15:32:37.926Z.

Quote observation: 2026-10-06T15:31:16.000Z. Amounts in USD. The price header may show a later quote.

Quote market capitalization: 4,751,544,777
Total debt · period ending 2026-06-30: 36,467,000
Cash · period ending 2026-06-30: 655,267,000
TTM operating income · period ending 2026-06-30: -227,544,000

FMP input reference: 3e31615b66e5acc6c2b7b3f8a521ec69124b31f47383f0f9627e8176a83f275d

EV/EBITDA|EV/Sales|Operating Income|All Metrics

Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.

DFTX EV/EBIT Ratio Metrics

EV/EBIT RATIO

N/A

DFTX Competitors' EV/EBIT Ratio

Definium Therapeutics, Inc.

Current

Market Cap

$4.75B

EV/EBIT Ratio

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

LifeStance Health Group, Inc.

Market Cap

$4.69B

EV/EBIT Ratio

59.53x

TTM Avg

192.46x

3Y Avg

192.46x

5Y Avg

192.46x

Option Care Health, Inc.

Market Cap

$4.65B

EV/EBIT Ratio

16.91x

TTM Avg

15.96x

3Y Avg

18.18x

5Y Avg

22.57x

BillionToOne, Inc.

Market Cap

$4.62B

EV/EBIT Ratio

97.38x

TTM Avg

157.20x

3Y Avg

157.20x

5Y Avg

157.20x

Oruka Therapeutics, Inc.

Market Cap

$4.91B

EV/EBIT Ratio

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

Dianthus Therapeutics, Inc.

Market Cap

$4.90B

EV/EBIT Ratio

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

Mirum Pharmaceuticals, Inc.

Market Cap

$4.94B

EV/EBIT Ratio

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

Indivior Pharmaceuticals Inc

Market Cap

$4.45B

EV/EBIT Ratio

9.14x

TTM Avg

11.90x

3Y Avg

40.42x

5Y Avg

37.42x

Adaptive Biotechnologies Corporation

Market Cap

$4.42B

EV/EBIT Ratio

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

Merit Medical Systems, Inc.

Market Cap

$5.09B

EV/EBIT Ratio

27.11x

TTM Avg

27.45x

3Y Avg

34.84x

5Y Avg

44.16x

NAME	MARKET CAP	EV/EBIT RATIO	TTM	3Y	5Y
Definium Therapeutics, Inc. (DFTX)	$4.75B	N/A	N/A	N/A	N/A
LifeStance Health Group, Inc. (LFST)vs ›	$4.69B	59.53x	192.46x	192.46x	192.46x
Option Care Health, Inc. (OPCH)vs ›	$4.65B	16.91x	15.96x	18.18x	22.57x
BillionToOne, Inc. (BLLN)vs ›	$4.62B	97.38x	157.20x	157.20x	157.20x
Oruka Therapeutics, Inc. (ORKA)vs ›	$4.91B	N/A	N/A	N/A	N/A
Dianthus Therapeutics, Inc. (DNTH)vs ›	$4.90B	N/A	N/A	N/A	N/A
Mirum Pharmaceuticals, Inc. (MIRM)vs ›	$4.94B	N/A	N/A	N/A	N/A
Indivior Pharmaceuticals Inc (INDV)vs ›	$4.45B	9.14x	11.90x	40.42x	37.42x
Adaptive Biotechnologies Corporation (ADPT)vs ›	$4.42B	N/A	N/A	N/A	N/A
Merit Medical Systems, Inc. (MMSI)vs ›	$5.09B	27.11x	27.45x	34.84x	44.16x

EV/EBIT Ratio Formula & Definition

EV/EBIT = Enterprise Value / EBIT (TTM)

Enterprise value to EBIT compares total company value to operating earnings, accounting for depreciation unlike EV/EBITDA.

Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute

Related Metrics

EV/EBITDA EV/Sales Operating Income All Metrics